Updates are available Correction dated 2023-07-27
Click to view Correction: https://doi.org/10.1186/s13063-023-07525-4
-
Authors
Jones, Caitlin MP http://orcid.org/0000-0002-9887-2493
Lin, Chung-Wei Christine http://orcid.org/0000-0001-6192-7238
Day, Richard O. http://orcid.org/0000-0002-6045-6937
Koes, Bart W. http://orcid.org/0000-0002-0450-9969
Latimer, Jane http://orcid.org/0000-0002-4809-5753
Maher, Chris G. http://orcid.org/0000-0002-1628-7857
McLachlan, Andrew http://orcid.org/0000-0003-4674-0242
Billot, Laurent http://orcid.org/0000-0002-4975-9793
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (APP1082480)
- License Information
-
More Information
Article History
Received: 15 April 2021
Accepted: 15 January 2022
First Online: 14 March 2022
Change Date: 27 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-023-07525-4
Declarations
:
: Ethics approval has been granted from the Human Research Ethics Committee, The University of Sydney (Project No. 2015-004).
: No identifiable participant data is contained in this publication. We are willing to provide a model consent form for participation in the OPAL trial upon request.
: AJM has received supplementary funding and/or trial medicines from GlaxoSmithKline and Pfizer (Australia) for investigator-initiated NHMRC-funded trials evaluating drug treatment of low back pain. He is also the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing. JL has received supplementary funding and/or trial medicines from GlaxoSmithKline and Pfizer (Australia) for investigator-initiated NHMRC-funded trials evaluating drug treatment of back pain. She has received funding from Baxter Biosciences for research evaluating musculoskeletal outcomes in children with haemophilia. ROD has received supplementary funding and/or trial medicines from GlaxoSmithKline and Pfizer (Australia) for investigator-initiated NHMRC-funded trials evaluating drug treatment of back pain. ROD has been a member of an advisory board about paracetamol for GlaxoSmithKline and ibuprofen for Reckitt Benckiser (Australia). Payments went to an audited hospital account for teaching and research purposes. CGM has received supplementary funding and/or trial medicines from GlaxoSmithKline and Pfizer (Australia) for investigator-initiated NHMRC-funded trials evaluating drug treatment of low back pain.
